Biopharma

Human medicines European public assessment report (EPAR): Camcevi, leuprorelin, Date of authorisation: 24/05/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Camcevi, leuprorelin, ...

Pharmaceuticals are spared from tariffs, for now

Pharmaceuticals are spared from tariffs, for now

Apr 3, 2025 0

And more crucial biotech news stories, brought to you by The Readout.

STAT+: Pharmalittle: We’re reading about a pharma tariff exception, FDA inspection cutbacks, and more

STAT+: Pharmalittle: We’re reading about a pharma tarif...

Apr 3, 2025 0

The Trump administration carved out an exception for pharmaceuticals from the pr...

Roche shows most Alzheimer's patients below amyloid threshold after 28 weeks

Roche shows most Alzheimer's patients below amyloid thr...

Apr 3, 2025 0

Roche has reported preliminary results on its Alzheimer’s disease prospect tront...

Aldeyra’s dry eye drug suffers second FDA rejection, but imminent data spur hope of fast recovery

Aldeyra’s dry eye drug suffers second FDA rejection, bu...

Apr 3, 2025 0

The FDA has set back Aldeyra Therapeutics’ ambitions to win approval for its dry...

Three Supreme Court health cases to keep an eye on

Three Supreme Court health cases to keep an eye on

Apr 3, 2025 0

Health news stories you need to read this morning.

Havas Health adds execs at nascent New York agency as Real Chemistry strengthens in Europe

Havas Health adds execs at nascent New York agency as R...

Apr 3, 2025 0

Agencies made moves on both sides of the Atlantic Wednesday, with Havas Health s...

Human medicines European public assessment report (EPAR): Tukysa, tucatinib, Date of authorisation: 11/02/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Tukysa, tucatinib, Dat...

Why a small journal’s ‘blueprint for NIH’ may offer clues to the agency’s future

Why a small journal’s ‘blueprint for NIH’ may offer clu...

Apr 3, 2025 0

A paper proposing NIH reforms is circulating in academic circles and within the ...

Reflection paper on use of real-world data in non-inter...

Apr 3, 2025 0

Reflection paper on use of real-world data in non-interventional studies to gene...

Journey towards a roadmap for regulatory guidance on re...

Apr 3, 2025 0

Journey towards a roadmap for regulatory guidance on real-world evidence

Real-world evidence

Real-world evidence

Apr 3, 2025 0

Real-world evidence

BeiGene abandons ociperlimab over poor phase 3 prospects in latest blow to TIGITs

BeiGene abandons ociperlimab over poor phase 3 prospect...

Apr 3, 2025 0

BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years ...

Human medicines European public assessment report (EPAR): Litak, cladribine, Date of authorisation: 14/04/2004, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Litak, cladribine, Dat...

Human medicines European public assessment report (EPAR): Yondelis, trabectedin, Date of authorisation: 17/09/2007, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Yondelis, trabectedin,...

Human medicines European public assessment report (EPAR): Hetronifly, serplulimab, Date of authorisation: 03/02/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Hetronifly, serplulima...

Human medicines European public assessment report (EPAR): Osenvelt, denosumab, Date of authorisation: 14/02/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Osenvelt, denosumab, D...

Biotech ‘megarounds’ hold steady as startups, VCs wait on IPOs

Biotech ‘megarounds’ hold steady as startups, VCs wait ...

Apr 3, 2025 0

More than three-quarters of private biotech investment tracked by BioPharma Dive...

STAT+: ‘This is an industry that everyone [bleeping] hates’

STAT+: ‘This is an industry that everyone [bleeping] ha...

Apr 3, 2025 0

Why health secretary RFK Jr. has it in for biotech.

Human medicines European public assessment report (EPAR): Rystiggo, Rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Rystiggo, Rozanolixizu...

Human medicines European public assessment report (EPAR): Bylvay, odevixibat, Date of authorisation: 16/07/2021, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Bylvay, odevixibat, Da...

Boehringer commits $31M to ADC R&D via new Swiss facility for NBE Therapeutics

Boehringer commits $31M to ADC R&D via new Swiss facili...

Apr 3, 2025 0

Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate...

Human medicines European public assessment report (EPAR): Copiktra, duvelisib, Date of authorisation: 19/05/2021, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Copiktra, duvelisib, D...

Scientific and technical recommendations: Veterinary Medicines Regulation

Scientific and technical recommendations: Veterinary Me...

Apr 3, 2025 0

Scientific and technical recommendations: Veterinary Medicines Regulation

38
39
40
41
42

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.